Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H de Mulder

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Cancer|October 1, 1993
Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II studyC J Punt, J T Burghouts, J J Croles, et al.
Cancer Immunology, Immunotherapy : CII|February 1, 1995
Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cellsL T Balemans, P A Steerenberg, B H Kremer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1993
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative GroupJ B Vermorken, J Verweij, P H de Mulder, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1988
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomitingL D de Haan, P H de Mulder, L V Beex, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatinP A van Liessum, C Seynaeve, P H de Mulder, et al.
British Journal of Cancer|March 25, 2000
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working PartyC M van Herpen, R L Jansen, W H Kruit, et al.
The Netherlands Journal of Medicine|January 1, 1985
Randomized neo-adjuvant chemotherapy trial for advanced head and neck cancerC Stolwijk, D J Wagener, P Van den Broek, et al.
Cancer|June 15, 1990
Hypothyroidism and goiter in a patient during treatment with interleukin-2V J Mattijssen, P H De Mulder, P A Van Liessum, et al.
Journal of Immunological Methods|April 6, 1988
A new radiometric assay for the quantitation of surface-bound IgG on sensitized erythrocytesJ G Van de Winkel, W J Tax, A Groeneveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 1999
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative GroupA S Planting, G Catimel, P H de Mulder, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Cancer|October 1, 1993
Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II studyC J Punt, J T Burghouts, J J Croles, et al.
Cancer Immunology, Immunotherapy : CII|February 1, 1995
Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cellsL T Balemans, P A Steerenberg, B H Kremer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1993
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative GroupJ B Vermorken, J Verweij, P H de Mulder, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1988
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomitingL D de Haan, P H de Mulder, L V Beex, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatinP A van Liessum, C Seynaeve, P H de Mulder, et al.
British Journal of Cancer|March 25, 2000
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working PartyC M van Herpen, R L Jansen, W H Kruit, et al.
The Netherlands Journal of Medicine|January 1, 1985
Randomized neo-adjuvant chemotherapy trial for advanced head and neck cancerC Stolwijk, D J Wagener, P Van den Broek, et al.
Cancer|June 15, 1990
Hypothyroidism and goiter in a patient during treatment with interleukin-2V J Mattijssen, P H De Mulder, P A Van Liessum, et al.
Journal of Immunological Methods|April 6, 1988
A new radiometric assay for the quantitation of surface-bound IgG on sensitized erythrocytesJ G Van de Winkel, W J Tax, A Groeneveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 1999
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative GroupA S Planting, G Catimel, P H de Mulder, et al.
Pageof 14